110192-21-7

Basic information

• Product Name: Carbamic acid, [2-(3-methoxyphenyl)ethyl]-, methyl ester
• CAS NO: 110192-21-7
• Molecular Formula: C11H15NO3
• Molecular Weight: 209.245
• Mol File: 110192-21-7.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-(3-methoxyphenyl)ethyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(3-methoxyphenyl)ethyl]-, methyl ester(110192-21-7)
• EPA Substance Registry System: Carbamic acid, [2-(3-methoxyphenyl)ethyl]-, methyl ester(110192-21-7)

Safety Data

• Hazardous Substances Data: 110192-21-7(Hazardous Substances Data)

Upstream product

• 79-22-1 methyl chloroformate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 

Downstream Products

• 74904-29-3 8-methoxy-3,4-dihydroisoquinolin-1(2H)-one 
• 22245-98-3 6-hydroxy-3,4-dihydro-2H-isoquinolin-1-one 
• 1340557-66-5 6-propoxy-1,2,3,4-tetrahydroisoquinoline 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Easy Access to 2,4-Disubstituted Cyclopentenones by a Gold(III)-Catalyzed A3-Coupling/Cyclization Cascade

An efficient and convenient synthesis of 2,4-disubstituted cyclopentenones has been achieved through a Au(III)-catalyzed isomerization-A3-coupling/cyclization cascade. A possible mechanism involving an initial Au(III)-catalyzed isomerization, A3-type coupling, and cyclization via an enol intermediate is postulated.

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode

PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT

The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according